Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling
Open Access
- 30 April 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (18), 4319-4330
- https://doi.org/10.1182/blood-2008-08-174300
Abstract
Inhibition of Wnt/β-catenin/T-cell factor (TCF) signaling induces proliferation of mesenchymal stem cells and/or suppresses their differentiation into osteoblasts (OBs). Osteolysis in multiple myeloma (MM) is related to the suppression of canonical Wnt signaling caused by DKK1, a soluble inhibitor of this pathway secreted by MM cells. Bortezomib (Bzb) can induce OB differentiation in vitro and in vivo and its anti-MM efficacy linked to bone anabolic effects. However, the molecular basis of the action of Bzb on bone is not completely understood. In the present study, we show that Bzb promotes matrix mineralization and calcium deposition by osteoprogenitor cells and primary mesenchymal stem cells via Wnt-independent activation of β-catenin/TCF signaling. Using affinity pull-down assays with immunoblotting and immunofluorescence, we found that Bzb induced stabilization of β-catenin. Nuclear translocation of stabilized β-catenin was associated with β-catenin/TCF transcriptional activity that was independent of the effects of Wnt ligand-receptor-induced signaling or GSK3β activation. Blocking the activation of β-catenin/TCF signaling by dominant negative TCF attenuated Bzb-induced matrix mineralization. These results provide evidence that Bzb induces OB differentiation via Wnt-independent activation of β-catenin/TCF pathway and suggest that proteasome inhibition therapy in MM may function in part by subverting tumor-induced suppression of canonical Wnt signaling in the bone microenvironment.Keywords
This publication has 60 references indexed in Scilit:
- The role of Dickkopf-1 in bone development, homeostasis, and diseaseBlood, 2009
- Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growthBlood, 2008
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myelomaBlood, 2008
- Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myelomaEuropean Journal of Haematology, 2008
- Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivoBlood, 2008
- Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceJCI Insight, 2008
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsBlood, 2007
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoBlood, 2006
- Expression of receptor activator of NF-?B ligand (RANKL) mRNA in human multiple myeloma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Human Osteoblasts Express a Repertoire of Cadherins, Which Are Critical for BMP‐2–Induced Osteogenic DifferentiationJournal of Bone and Mineral Research, 1998